A comparative study of morbidity and symptom severity among double-J stented patients with and without tamsulosin administration

Authors

  • Abhiram Kucherlapati Department of Urology, Narayana Medical College, Nellore, Andhra Pradesh, India
  • Dinesh K. Ravi Department of Urology, Narayana Medical College, Nellore, Andhra Pradesh, India
  • Udit Jain Department of Urology, Narayana Medical College, Nellore, Andhra Pradesh, India
  • Sreedhar Dayaphule Department of Urology, Narayana Medical College, Nellore, Andhra Pradesh, India
  • Bathalapalli R. Theja Department of Urology, Narayana Medical College, Nellore, Andhra Pradesh, India
  • Faisal Jagirdar Department of Urology, Narayana Medical College, Nellore, Andhra Pradesh, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20241540

Keywords:

Tamsulosin, DJ stent, Lower urinary tract symptoms, Endourology

Abstract

Background: The insertion of a double-J (DJ) stent is considered a routine and necessary urological procedure. The symptoms produced by the stent are predominantly irritative in nature and the use of alpha blockers like tamsulosin have shown considerable in treating the stent associated symptom. Aim of the study was to assess tamsulosin's impact on ureteral stent-associated morbidity.

Methods: A comparative cross-sectional study. All the patients with ureteric calculi admitted in the department of urology, Narayana Hospital, Nellore, Andhra Pradesh.

Results: A total of 80 patients who met the inclusion criteria, were divided into two groups. Group A receiving placebo and group B receiving tamsulosin 0.4 mg. Among the study population, there was statistically significant difference between the means of parameters between the groups during the stent removal. The means of group B were significantly lower than the means of group A which shows that tamsulosin is very effective in managing the pain and also the stent related morbidity.

Conclusions: Tamsulosin is very effective in managing the pain and also the stent related morbidity, which was measured by international prostate symptom score (IPSS) score – both obstructive and irritative. The quality of life was suggestively better in tamsulosin group.

 

References

Byrne RR, Auge BK, Kourambas J. Routine ureteral stenting is not necessary after ureteroscopy and ureteropyeloscopy: a randomized trial. J Endourol. 2002;16:9-13.

Joshi HB, Okeke A, Newns N, Keeley FX Jr, Timoney AG. Characterization of urinary symptoms in patients with ureteral stents. Urology. 2002;59:511-9.

Schulman CC, Lock TM, Buzelin JM. Longterm use of tamsulosin to treat lower urinary tract symptoms/benign prostatic hyperplasia. J Urol. 2001;166:1358-63.

Hsiao SM, Lin HH, Kuo HC. International Prostate Symptom Score for assessing lower urinary tract dysfunction in women. Int Urogynecol J. 2013;24(2):263-7.

Cam K, Akman Y, Cicekci B, Senel F,Erol A. Mode of administration of international prostate symptom score in patients with lower urinary tract symptoms: physician vs self. Prostate Cancer Prostatic Dis. 2004;7(1):414.

Ata Ur Rehman R, Tahir MM, Seerwan M. Effect of tamsulosin on stent related symptoms; a prospective study. Professional Med J. 2016;23(1):114-8.

Chew BH, Knudsen BE, Denstedt JD. The use of stents in contemporary urology. Curr Opin Urol. 2004;14:111-5.

Denstedt JD, Reid G, Sofer M. Advances inureteral stent technology. World J Urol. 2000;18:237-42.

Beiko DT, Knudsen BE, Denstedt JD. Advances in ureteral stent design. J Endourol. 2003;17:195-9.

Candela JV, Bellman GC. Ureteral stents: impact of diameter and composition on patient symptoms. J Endourol. 1997;11:45-7.

Thomas R. Indwelling ureteral stents: impact of material and shape on patient comfort. J Endourol. 1993;7:137-40.

Joshi HB, Newns N, Stainthorpe A, MacDonagh RP, Keeley FX, Timoney AG. Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure. J Urol. 2003;169:1060-4.

Shalaby E, Ahmed AF, Maarouf A, Yahia I, Ali M, Ghobish A. Randomized controlled trial to compare the safety and efcacy of tamsulosin, solifenacin, and combination of both in treatment of double-J stent related lower urinary symptoms. Adv Urol. 2013;752382.

Duvdevani M, Chew BH, Denstedt JD. Minimizing symptoms in patients with ureteric stents. Curr Opin Urol. 2006;16(2):77-82.

Thomas R. Indwelling ureteral stents: impact of material and shape on patient comfort. J Endourol. 1993;7(2):137-40.

Shah Y, Trivedi M, Lad V, Modi J, Bochiya G. A clinical study of effects of tamsulosin in ureteric stent related morbidity. Int Surg J. 2023;10:392-8.

Singh R, Bhangu GS, Bansal D, Rattan A. Effect of tamsulosin on ureteric stent related morbidity: a double-blind randomized placebo-controlled study. Int Surg J. 2021;8:294-9.

Downloads

Published

2024-05-31

How to Cite

Kucherlapati, A., Ravi, D. K., Jain, U., Dayaphule, S., Theja, B. R., & Jagirdar , F. (2024). A comparative study of morbidity and symptom severity among double-J stented patients with and without tamsulosin administration. International Journal of Research in Medical Sciences, 12(6), 1953–1956. https://doi.org/10.18203/2320-6012.ijrms20241540

Issue

Section

Original Research Articles